Traverse Biotech, Inc

📢 Exciting News! Traverse Biotech is heading to the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, TX, from November 6-10, 2024. Our team, including CEO Brandy Houser, PhD, and Director of Strategy & Operations Jing Gong, PhD, will present new data on TB-Bs1, our ROR2-targeted T-cell engager, showcasing its therapeutic potential in ROR2-positive solid tumors. 📑 Poster Presentation Details: - Title: ROR2-targeted T-cell engager as a novel therapeutic approach in solid tumors - Abstract Number: 1065 - Location: Exhibit Halls A-B, George R. Brown Convention Center - Date: Friday, November 8, 2024 Join us as we share preclinical findings and be part of the discussion around the forefront of immunotherapy in the fight against cancer. For more info, see: https://lnkd.in/g5HmHDjh #TraverseBiotech #SITC2024 #Immunotherapy #CancerResearch #ROR2 #TCellEngager

We are pleased to announce that Bob Dufour has officially joined Traverse Biotech, Inc. as Chief Business Officer! We are grateful for his invaluable expertise and look forward to his leadership as Traverse Biotech enters an exciting new phase. Prior to joining Traverse Biotech, Bob served as Partner at Cormis, where he co-founded the US division and led business development and client delivery. His extensive background in the pharmaceutical industry includes pivotal roles at Abbott Canada, Wyeth, and Auxilium Pharmaceuticals, and his strategic oversight at Veloxis Pharmaceuticals, where he established and launched the company's commercial operations. Throughout his career, Bob has made significant contributions in various therapeutic areas, including infectious diseases, transplant immunology, hematology, and oncology. His deep experience in these areas, combined with his ability to drive business growth and strategic partnerships, will be instrumental in advancing Traverse Biotech’s development and commercial strategies. Mr. Dufour holds a robust track record of successful leadership roles across various functions including Finance, Business Development, Sales, and Marketing. His strategic acumen and comprehensive industry knowledge will significantly enhance our executive team's capabilities. We are thrilled to welcome him aboard the #Traverse #Biotech Team. For more details, please visit our website: https://lnkd.in/gz5mKVvn

Traverse Biotech will be at BioEquity Europe 2024! We look forward to connecting with companies and investors in San Sebastian, Spain. Our CEO, Brandy Houser, PhD, will be introducing Traverse and providing updates on our our pipeline. As part of the New Wave companies’ lineup, Dr. Houser's talk will explore our original partnership model and commitment to developing immunotherapies for underserved pathologies. Don’t miss it, the presentation is scheduled for 3:30 pm CET on May 13th.  🤝 We are grateful to BioCentury team for this opportunity to highlight our work and explore potential collaborations that will help accelerate the availability of our therapies to patients worldwide. 🌐 At Traverse Biotech, we're dedicated to leveraging clinically validated platforms to advance novel immunotherapies that can tackle a wide range of conditions. Our mission is to bring these transformative treatments to the global market, ensuring they reach people of all ages living with underserved pathologies. 💡 About BioEquity Europe 2024: BioEquity Europe is the premier conference for financial dealmakers, investors, pharmaceutical executives, and biotech innovators. It provides an essential platform  for startups like ours to demonstrate their innovations and for industry leaders to find new opportunities for collaboration. 📧 For more info about Traverse Biotech and our efforts, find us at: https://lnkd.in/eTZaQSQ4 See you in San Sebastian! 🚀 #BioEquityEurope2024 #Immunotherapy #HealthcareInnovation #Biotech #TraverseBiotech Jean-Loup Romet-Lemonne, MD Emmanuelle Voisin, PhD

We are excited to announce that the National Institute of Allergy and Infectious Diseases (NIAID) is supporting the development of our pipeline candidate, an innovative innate immune modulator. This support will accelerate our efforts to tackle myeloid dysfunction in various disease pathologies, including metastatic lung disease. To learn more about this groundbreaking initiative, please visit: https://lnkd.in/gKyEQyP3 #immunemodulator #biotech #NIAID #NIH #Traverse

We are pleased to announce that after several years as an advisor, Olivier AUDEMARD has officially joined Traverse Biotech, Inc as Chief Financial Officer, effective March 1st, 2024. We are grateful for his continued contributions and leadership as Traverse moves into its exciting next phase. Prior to joining Traverse Biotech, Olivier was Managing Director and Head of the Structured Finance activities at Credit Agricole Americas in New York. He has had a distinguished career at both Credit Agricole and Crédit Lyonnais, having held prominent roles within Investment Banking in Paris and London before his tenure in New York. Olivier's adeptness in navigating complex financial landscapes and structuring strategic investments will be instrumental in supporting Traverse Biotech's financial strategies and growth initiatives. Mr. Audemard holds a Master’s degree in Economy and Econometrics from the University François Rabelais in the Loire Valley (France). He is a graduate of the Institut d'Etudes Politiques de Paris (Sciences-Po) with a specialization in Business and Finance. We are thrilled to have him as part of the #Traverse #Biotech Team. See our website for more details: https://lnkd.in/gBvJp8cp

We are pleased to announce that after several years as an advisor, Olivier AUDEMARD has officially joined Traverse Biotech, Inc as Chief Financial Officer, effective March 1st, 2024. We are grateful for his continued contributions and leadership as Traverse moves into its exciting next phase. Prior to joining Traverse Biotech, Olivier was Managing Director and Head of the Structured Finance activities at Credit Agricole Americas in New York. He has had a distinguished career at both Credit Agricole and Crédit Lyonnais, having held prominent roles within Investment Banking in Paris and London before his tenure in New York. Olivier's adeptness in navigating complex financial landscapes and structuring strategic investments will be instrumental in supporting Traverse Biotech's financial strategies and growth initiatives. Mr. Audemard holds a Master’s degree in Economy and Econometrics from the University François Rabelais in the Loire Valley (France). He is a graduate of the Institut d'Etudes Politiques de Paris (Sciences-Po) with a specialization in Business and Finance. We are thrilled to have him as part of the #Traverse #Biotech Team. See our website for more details: https://lnkd.in/gBvJp8cp